Suying Song, MD
Neurology · Staten Island, NYNPI 1518040716
Payments from drug & device makers
Across 131 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$265
- EMD Serono, Inc.$171
- AstraZeneca$171
- UCB, Inc.$153
- Biogen$149
- Novartis$144
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$703%
- Food & beverage$2,29297%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 14 | $265 |
| EMD Serono, Inc. | 10 | $171 |
| AstraZeneca | 7 | $171 |
| UCB, Inc. | 7 | $153 |
| Biogen | 7 | $149 |
| Novartis | 8 | $144 |
| Supernus Pharmaceuticals, Inc. | 9 | $138 |
| Eisai Inc. | 7 | $120 |
| Mallinckrodt Enterprises LLC | 7 | $111 |
| Tanabe Pharma America, Inc. | 5 | $94 |
| Teva Pharmaceuticals USA, Inc. | 5 | $87 |
| Grifols USA, LLC | 4 | $87 |
| Lilly USA, LLC | 6 | $78 |
| Amgen | 3 | $73 |
| Acorda Therapeutics, Inc | 4 | $70 |
| Pfizer | 4 | $54 |
| Livanova USA, Inc. | 3 | $50 |
| GE HealthCare | 3 | $41 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| Upsher-smith Laboratories LLC | 2 | $37 |
| Sanofi | 2 | $37 |
| Adamas Pharmaceuticals, Inc. | 2 | $36 |
| Neurocrine Biosciences, Inc. | 2 | $32 |
| CSL Behring | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| AbbVie | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
How this compares
$2,368 in reported general payments places this provider in the 55th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 45 | $970,755 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 44 | $677,261 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 28 | $504,109 |
| CopaxoneGlatiramer Acetate | 53 | $328,782 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 12 | $263,948 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $136,733 |
| GlatopaGlatiramer Acetate | 35 | $103,136 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 15 | $87,277 |
| Teriflunomide | 26 | $36,930 |
| Lamotrigine ErLamotrigine | 49 | $25,604 |
| Lacosamide | 112 | $14,390 |
| VimpatLacosamide | 11 | $12,943 |
| Levetiracetam | 261 | $9,196 |
| Gabapentin | 375 | $7,793 |
| Levetiracetam ErLevetiracetam | 125 | $7,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $22 | $677,26144 claims |
| Grifols USA, LLCGamunex-C | $87 | $504,10928 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $87 | $328,78253 claims |
| PfizerOctagam | $54 | $263,94812 claims |
| UCB, Inc.Vimpat | $153 | $12,94311 claims |
| Upsher-smith Laboratories LLCTopiramate | $37 | $3,276169 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $20 | $3,17812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,623 neurology providers in New York.
Other neurology in Staten Island
- Allan PerelStaten Island$1.8M
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.